Source:http://linkedlifedata.com/resource/pubmed/id/12019082
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
2002-5-20
|
pubmed:abstractText |
beta-L-Thymidine (L-dT) and beta-L-2'-deoxycytidine (L-dC) are potent and highly specific inhibitors of hepatitis B virus (HBV) replication both in vivo and in vitro (50% effective concentrations, 0.19 to 0.24 microM in 2.2.15 cells). The intracellular metabolisms of L-dT and L-dC were investigated in HepG2 cells and primary cultured human hepatocytes. L-dT and L-dC were extensively phosphorylated in both cell types, with the 5'-triphosphate derivative being the predominant metabolite. In HepG2 cells, the 5'-triphosphate levels were 27.7 +/- 12.1 and 72.4 +/- 1.8 pmol/10(6) cells for L-dT and L-dC, respectively. In primary human hepatocytes, the 5'-triphosphate levels were 16.5 +/- 9.8 and 90.1 +/- 36.4 pmol/10(6) cells for L-dT and L-dC, respectively. Furthermore, a choline derivative of L-dCDP was detected at concentrations of 15.8 +/- 1.8 and 25.6 +/- 0.1 pmol/10(6) cells in human hepatocytes and HepG2 cells, respectively. In HepG2 cells exposed to L-dC, the 5'-monophosphate and 5'-triphosphate derivatives of beta-L-2'-deoxyuridine (L-dUMP and L-dUTP, respectively) were also observed, reaching intracellular concentrations of 6.7 +/- 0.4 and 18.2 +/- 1.0 pmol/10(6) cells, respectively. In human hepatocytes, L-dUMP and L-dUTP were detected at concentrations of 5.7 +/- 2.4 and 43.5 +/- 26.8 pmol/10(6) cells, respectively. It is likely that deamination of L-dCMP by deoxycytidylate deaminase leads to the formation of L-dUMP, as the parent compound, L-dC, was not a substrate for deoxycytidine deaminase. The intracellular half-lives of L-dTTP, L-dCTP, and L-dUTP were at least 15 h, with intracellular concentrations of each metabolite remaining above their respective 50% inhibitory concentrations for the woodchuck hepatitis virus DNA polymerase for as long as 24 h after removal of the drug from cell cultures. Exposure of HepG2 cells to L-dT in combination with L-dC led to concentrations of the activated metabolites similar to those achieved with either agent alone. These results suggest that the potent anti-HBV activities of L-dT and L-dC are associated with their extensive phosphorylation.
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/12019082-11120971,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12019082-1321132,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12019082-1336341,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12019082-2139281,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12019082-2430286,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12019082-2834034,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12019082-7628294,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12019082-8092819,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12019082-8328741,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12019082-8385948,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12019082-8781347,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12019082-8960066,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12019082-9011789,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12019082-9705540
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0066-4804
|
pubmed:author |
pubmed-author:BridgesE GEG,
pubmed-author:BryantM LML,
pubmed-author:Cretton-ScottEE,
pubmed-author:DukhanDD,
pubmed-author:FarajAA,
pubmed-author:GosselinGG,
pubmed-author:Hernandez-SantiagoBB,
pubmed-author:ImbachJ LJL,
pubmed-author:PierreOO,
pubmed-author:PlacidiLL,
pubmed-author:Rodriguez-OrengoJJ,
pubmed-author:SommadossiJ PJP
|
pubmed:issnType |
Print
|
pubmed:volume |
46
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1728-33
|
pubmed:dateRevised |
2009-11-18
|
pubmed:meshHeading |
pubmed-meshheading:12019082-Antiviral Agents,
pubmed-meshheading:12019082-Carcinoma, Hepatocellular,
pubmed-meshheading:12019082-Chromatography, High Pressure Liquid,
pubmed-meshheading:12019082-Deoxycytidine,
pubmed-meshheading:12019082-Half-Life,
pubmed-meshheading:12019082-Hepatitis B,
pubmed-meshheading:12019082-Hepatitis B virus,
pubmed-meshheading:12019082-Hepatocytes,
pubmed-meshheading:12019082-Humans,
pubmed-meshheading:12019082-Liver Neoplasms,
pubmed-meshheading:12019082-Phosphorylation,
pubmed-meshheading:12019082-Thymidine,
pubmed-meshheading:12019082-Tumor Cells, Cultured
|
pubmed:year |
2002
|
pubmed:articleTitle |
Pharmacology of beta-L-thymidine and beta-L-2'-deoxycytidine in HepG2 cells and primary human hepatocytes: relevance to chemotherapeutic efficacy against hepatitis B virus.
|
pubmed:affiliation |
Department of Pharmacology, University of Alabama at Birmingham, USA.
|
pubmed:publicationType |
Journal Article
|